Photo from wikipedia
Over one third of the 47,600 opioid overdose deaths in 2017 involved prescription opioids. Co-prescribing naloxone—an overdose reversal agent—alongside high-risk opioid therapy has been championed as a harm reduction practice… Click to show full abstract
Over one third of the 47,600 opioid overdose deaths in 2017 involved prescription opioids. Co-prescribing naloxone—an overdose reversal agent—alongside high-risk opioid therapy has been championed as a harm reduction practice for preventing fatal overdoses. While naloxone co-prescribing is uncommon overall, little is known about trends in naloxone prescribing in the Medicare population, which has experienced recent increases in opioid overdose. 5 The objective of this study was to describe patterns of naloxone-prescribing engagement among frequent opioid prescribers using the Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File from 2013 to 2017.
Journal Title: Journal of General Internal Medicine
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!